市值近700亿港元、上半年收入预增超60%,如何读懂药明合联的生意经?

Ofweek维科网
25 Jul

近段时间预交成绩单的一众医药企业中,药明系的表现依旧夺目。7月23日,药明合联发布了正面盈利预告,其预期2025年上半年收入增长超过60%,净利润增长超50%,经调整净利润(不含利息收入及开支)增长超67%。增长速度仍然迅猛。要知道,从2020年成立到2024年,短短几年间药明合联实现了从1亿元到40.52亿元的营收暴涨,这速度就像“开了挂”。药明合联业绩起飞,资本市场的热情也高涨。业绩预告公布...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10